These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9915441)

  • 1. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
    Roberts RO; Bergstralh EJ; Katusic SK; Lieber MM; Jacobsen SJ
    J Urol; 1999 Feb; 161(2):529-33. PubMed ID: 9915441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000.
    Mullan RJ; Jacobsen SJ; Bergstralh EJ; Slezak JM; Tindall DJ; Lieber MM; Roberts RO
    BJU Int; 2005 May; 95(7):951-5. PubMed ID: 15839911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.
    Merrill RM; Stephenson RA
    J Urol; 2000 Feb; 163(2):503-10. PubMed ID: 10647666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
    J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997.
    Roberts RO; Bergstralh EJ; Peterson NR; Bostwick DG; Lieber MM; Jacobsen SJ
    J Urol; 2000 May; 163(5):1471-5. PubMed ID: 10751860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
    Tonita JM; Skarsgard D; Muhajarine N
    Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
    Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
    J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
    Connolly D; Black A; Gavin A; Keane PF; Murray LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of screening on prostate cancer rates and trends.
    Mettlin C
    Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? Estimating the broader economic influences on aggregate prostate cancer mortality rates.
    Di Matteo L; Di Matteo R
    Eur J Health Econ; 2005 Dec; 6(4):298-308. PubMed ID: 16180027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA testing in Austria: induced morbidity and saved mortality.
    Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
    Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer and the Will Rogers phenomenon.
    Albertsen PC; Hanley JA; Barrows GH; Penson DF; Kowalczyk PD; Sanders MM; Fine J
    J Natl Cancer Inst; 2005 Sep; 97(17):1248-53. PubMed ID: 16145045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
    Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
    BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downward trend in prostate cancer mortality in Quebec and Canada.
    Meyer F; Moore L; Bairati I; Fradet Y
    J Urol; 1999 Apr; 161(4):1189-91. PubMed ID: 10081867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer incidence and survival in relation to education (United States).
    Steenland K; Rodriguez C; Mondul A; Calle EE; Thun M
    Cancer Causes Control; 2004 Nov; 15(9):939-45. PubMed ID: 15577296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer in American Indians, New Mexico, 1969 to 1994.
    Gilliland FD; Key CR
    J Urol; 1998 Mar; 159(3):893-7; discussion 897-8. PubMed ID: 9474177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.